Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
OMB No. 0925-0001/0002 (Rev. 08/12 Approved Through 8/31/2015) BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. DO NOT EXCEED FIVE PAGES. NAME: Lund, Jennifer L. eRA COMMONS USER NAME (agency login): JENLUND POSITION TITLE: Assistant Professor EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.) INSTITUTION AND LOCATION Tufts University, Medford, MA University of North Carolina at Chapel Hill, Chapel Hill, NC University of North Carolina at Chapel Hill, Chapel Hill, NC Aarhus University (Denmark), Aarhus DEGREE (if applicable) Completion Date MM/YYYY BA MSPH 05/2003 12/2009 Economics/International Relations Epidemiology PHD 12/2011 Epidemiology OTH 09/2013 Clinical Epidemiology FIELD OF STUDY A. Personal Statement I am a pharmacoepidemiologist with substantive interests in aging, multimorbidity and oncology and expertise in health services and comparative effectiveness research. The overall objective of my research is to generate robust evidence regarding the uses, benefits and harms of medical interventions that will lead to improved medical decisions, clinical outcomes and quality of life for older cancer patients. My research in geriatric oncology primarily addresses: 1) the quality of cancer care, 2) the effectiveness and safety of cancer treatment options and 3) the role of polypharmacy, multimorbidity, and frailty in cancer treatment selection and outcomes. Through my PhD training, I developed a broad set of analytic tools, including focused training in state-of-the-art epidemiologic methods and their application to study the utilization and impact of cancer treatments among older adults. My dissertation work drew upon the Surveillance, Epidemiology and End Results program (SEER)-Medicare database to examine patterns of chemotherapy uptake and investigate patient, physician, and hospital factors associated with the dissemination of innovative treatments among older colorectal cancer patients. I also have international experience using large linked databases in Canada and Denmark. Currently, I am using SEER-Medicare data to develop my research portfolio in geriatric oncology and have obtained funding for studies relevant to this application, including: 1) a pilot grant through NC TraCS to develop methods to improve the measurement of frailty and comorbidity among older cancer patients using administrative data, 2) a PhRMA foundation grant evaluating heterogeneity of the comparative effectiveness of chemotherapy options among older colon cancer patients and 3) a K12 Paul Calabresi Clinical Oncology Career Development Award to evaluate polypharmacy, chemotherapy and adverse outcomes among older cancer patients. 1. Lund JL, Stürmer T, Harlan LC, Sanoff HK, Sandler RS, Brookhart MA, Warren JL. Identifying specific chemotherapeutic agents in Medicare data: a validation study. Med Care. 2013 May;51(5):e27-34. PubMed PMID: 22080337; PubMed Central PMCID: PMC3290707. 2. Lund JL, Stürmer T, Sanoff HK, Brookhart A, Sandler RS, Warren JL. Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients. Cancer. 2013 Jun 1;119(11):2038-47. PubMed PMID: 23512326; PubMed Central PMCID: PMC3663924. 3. Lund JL, Frøslev T, Deleuran T, Erichsen R, Nilsson T, Pedersen AN, Høyer M. Validity of the Danish National Registry of Patients for chemotherapy reporting among colorectal cancer patients is high. Clin Epidemiol. 2013;5:327-34. PubMed PMID: 24039450; PubMed Central PMCID: PMC3770491. B. Positions and Honors Positions and Employment 2003 - 2004 Associate Analyst, Healthcare Antitrust Practice, National Economic Research Associates, White Plains, NY 2005 - 2007 Senior Consultant, International Transfer Pricing Economics, Ernst & Young LLP, New York, NY 2007 - 2009 Research Assistant, Department of Epidemiology, UNC-Chapel Hill , Chapel Hill, NC 2008 - 2008 Summer Fellow, National Cancer Institute, Applied Research Program, Rockville, MD 2009 - 2011 Research Assistant, Worldwide Epidemiology, GlaxoSmithKline , Research Triangle Park, NC 2009 - 2011 Pre-Doctoral Trainee, School of Medicine, Division of Gastroenterology and Hepatology, UNCChapel Hill, Chapel Hill, NC 2010 - 2012 Teaching Assistant, Department of Epidemiology, UNC-Chapel Hill, Chapel Hill, NC 2012 - 2013 Consultant, New England Research Institute, Watertown, MA 2012 - 2013 Consultant, GlaxoSmithKline, Research Triangle Park, NC 2012 - 2013 Post-Doctoral Fellow, Department of Clinical Epidemiology, Aarhus University, Aarhus 2013 Assistant Professor, Department of Epidemiology, UNC-Chapel Hill, Chapel Hill, NC Other Experience and Professional Memberships 2009 Member, Society of Epidemiological Research (SER) 2009 Member, International Society of Pharmacoepidemiology (ISPE) 2011 Member, American Society of Clinical Oncology (ASCO) Honors 2003 2003 2008 2010 2011 2011 2012 2013 2015 Graduated summa cum laude, Tufts University Audrey L. Hale Prize recipient, Tufts University Methodologies in Healthcare Outcomes in Gastroenterology Trainee Scholarship Recipient, Gastroenterology Research Group (GRP) and the American Gastroenterological Association Scholarship Recipient, 26th Annual Meeting for the International Society for Pharmacoepidemiology Student Dissertation Workshop Participant, Society for Epidemiologic Research, 3rd Annual North American Congress of Epidemiology Student Travel Scholarship Award Recipient, Society for Epidemiologic Research, 3rd Annual North American Congress of Epidemiology Delta Omega Honor Society Member, Theta Chapter, UNC-Chapel Hill Abstract Achievement Award winner, American Society of Hematology Gordon H. DeFriese Career Development in Aging Research Award, UNC-Chapel Hill C. Contribution to Science 1. Evaluation of patterns of colorectal cancer treatment. My research seeks to describe patterns of colorectal cancer (CRC) treatment across a variety of populations in order to evaluate the quality of care received. CRC mortality has steadily declined over the past decades in the United States, in part due to advances in treatment. However, the dissemination and uptake of new CRC therapies varies in some settings according to patients’ age, race/ethnicity, socioeconomic status and level of comorbidity. The “appropriateness” of CRC treatment among older cancer patients is particularly complex due to the high prevalence of multimorbidity and competing health risks. As the population ages and new therapies are developed, uncertainties surrounding optimal treatment approaches for older cancer patients will need to be addressed. a. Chawla N, Butler EN, Lund J, Warren JL, Harlan LC, Yabroff KR. Patterns of colorectal cancer care in Europe, Australia, and New Zealand. J Natl Cancer Inst Monogr. 2013;2013(46):36-61. PubMed PMID: 23962509; PubMed Central PMCID: PMC3888187. b. Butler EN, Chawla N, Lund J, Harlan LC, Warren JL, Yabroff KR. Patterns of colorectal cancer care in the United States and Canada: a systematic review. J Natl Cancer Inst Monogr. 2013;2013(46):13-35. PubMed PMID: 23962508; PubMed Central PMCID: PMC3859290. c. Lund JL, Stürmer T, Sanoff HK, Brookhart A, Sandler RS, Warren JL. Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients. Cancer. 2013 Jun 1;119(11):2038-47. PubMed PMID: 23512326; PubMed Central PMCID: PMC3663924. d. Murphy CC, Harlan LC, Lund JL, Lynch CF, Geiger AM. Patterns of colorectal cancer care in the United States: 1990-2010. Journal of the National Cancer Institute. Forthcoming; 2. Validation of cancer treatments identified using administrative claims and cancer registry data. My research also assesses the validity of large administrative and cancer registry data for identifying cancer treatments, including surgery, radiation therapy, hormone therapy and chemotherapy across a variety of cancer sites. In the era of “big data,” these resources (and others, including electronics medical records) are increasingly being used to evaluate the dissemination, benefits and harms of cancer treatments in “real world” settings. However, misclassification of cancer treatments could bias estimates of frequency and association, warranting continued monitoring and validation, particularly as new therapies are introduced to the market. a. Lund JL, Frøslev T, Deleuran T, Erichsen R, Nilsson T, Pedersen AN, Høyer M. Validity of the Danish National Registry of Patients for chemotherapy reporting among colorectal cancer patients is high. Clin Epidemiol. 2013;5:327-34. PubMed PMID: 24039450; PubMed Central PMCID: PMC3770491. b. Lund JL, Stürmer T, Harlan LC, Sanoff HK, Sandler RS, Brookhart MA, Warren JL. Identifying specific chemotherapeutic agents in Medicare data: a validation study. Med Care. 2013 May;51(5):e27-34. PubMed PMID: 22080337; PubMed Central PMCID: PMC3290707. c. Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, Warren JL. Comparison of SEER Treatment Data with Medicare Claims. Med Care. 2014 Mar 15;PubMed PMID: 24638121. 3. Description of economic burden of cancer. My research also addresses the economic burden of cancer survivorship. Given the rising price tag of cancer drugs and changes in insurance coverage due to the Affordable Care Act, the impact of a cancer diagnosis and treatment on patients’ out-of-pocket medical spending varies widely, but on average is increasing. However, my work with colleagues at the National Cancer Institute has drawn attention to the fact that the “costs” or economic burden of cancer are not only those incurred by patients directly through their interaction with the healthcare system (e.g., surgery, hospitalization, chemotherapy), but encompass a wide range of indirect (e.g., time spent seeking medical care for patients and caregivers, time lost from work, etc.) and psychosocial (e.g., decreases in quality of life through feelings of loneliness, anxiety, loss of control, etc.)) costs. This collaborative work highlights the need for further research into the multidimensional nature of the costs of cancer care and their impact on the patient experience, which will serve to shape future health care policies to improve the cancer survivorship experience. a. Lund JL, Yabroff KR, Ibuka Y, Russell LB, Barnett PG, Lipscomb J, Lawrence WF, Brown ML. Inventory of data sources for estimating health care costs in the United States. Med Care. 2009 Jul;47(7 Suppl 1):S127-42. PubMed PMID: 19536009; PubMed Central PMCID: PMC3097385. b. Lund JL, Yabroff KR. Cancer Rehabilitation and Survivorship: A Transdisciplinary Approach. Lester J, Schmitt P, editors. Pittsburgh, PA: Oncology Nursing Society; 2011. Chapter 23, Economic Burden of Cancer Survivorship in the United States; p.239-46. c. Tompa E, Lund JL, Yabroff KR. Health Services for Cancer Survivors: Practice, Policy and Research. Feuerstein M, Ganz PA, editors. New York, NY: Springer; 2011. Chapter 15, Health Economics and Cancer Survivorship; p.299-328. d. Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2006-14. PubMed PMID: 21980008; PubMed Central PMCID: PMC3191884. Complete List of Published Work in My Bibliography: http://www.ncbi.nlm.nih.gov/myncbi/1zIfcqiKRRckm/bibliography/40957013/public/?sort=date&direction=ascen ding D. Research Support Awarded NA PI (Sharpless) 07/01/15-06/30/17 K12 Paul Calabresi Career Development Award for Clinical Oncology – UNC-Chapel Hill Medication use, chemotherapy and adverse outcomes among older cancer patients This study will use the SEER-Medicare database to describe the prevalence and outcomes of polypharmacy, potentially inappropriate medication use and medications with the potential to interact with chemotherapy among older adults initiating chemotherapy for the treatment of non-metastatic breast, colon and lung cancer or non-Hodgkin lymphoma. Ongoing Research Support NA PI (Lund) 01/01/15-12/31/15 PhRMA Foundation Evaluating the heterogeneity of cancer treatment benefits among older adults The goal of this study is to evaluate whether claims-based measures of multimorbidity and frailty modify the comparative effectiveness of adjuvant chemotherapy with and without oxaliplatin among older stage III colon cancer patients using the SEER-Medicare linked data. Role: PI 550KR61327 PI (Lund, Sanoff) 06/01/14-05/31/15 NC TraCS Pilot Award (1UL1TR001111) Improved measurement of patient frailty and comorbidity for targeting subgroups of older adults in cancer comparative effectiveness research This study will develop and validate claims-based measures of patient frailty and severity of comorbid disease using two data sources: the SEER-Medicare linked data and the Medicare Current Beneficiary Survey. Role: Co-PI Completed Research Support T32 DK007634-22 PI (Sandler) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Digestive Disease Epidemiology Training Program Role: TA 07/10/90-06/30/14